52
Participants
Start Date
August 14, 2025
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
nanoliposomal irinotecan plus carboplatin
"Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria."
Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung City
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Chang Gung Memorial Hospital (Lin-Kou),, Linkou District
China Medical University Hospital, Taichung
National Cheng-Kung University Hospital, Tainan City
Taipei Veterans General Hospital, Taipei
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Chang Gung Memorial Hospital
OTHER
China Medical University Hospital
OTHER
National Cheng-Kung University Hospital
OTHER
Kaohsiung Medical University Chung-Ho Memorial Hospital
OTHER
National Health Research Institutes, Taiwan
OTHER